BRPI0415249A - terapia de combinação para infecção por hcv - Google Patents

terapia de combinação para infecção por hcv

Info

Publication number
BRPI0415249A
BRPI0415249A BRPI0415249-2A BRPI0415249A BRPI0415249A BR PI0415249 A BRPI0415249 A BR PI0415249A BR PI0415249 A BRPI0415249 A BR PI0415249A BR PI0415249 A BRPI0415249 A BR PI0415249A
Authority
BR
Brazil
Prior art keywords
hcv infection
present
combination therapy
relates
combinations
Prior art date
Application number
BRPI0415249-2A
Other languages
English (en)
Inventor
Ene Ette
John J Alam
Robert Stephen Kauffman
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of BRPI0415249A publication Critical patent/BRPI0415249A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"TERAPIA DE COMBINAçãO PARA INFECçãO POR HCV". A presente invenção refere-se à combinações terapêuticas compreendendo VX-497, ribavirina e interferon. A presente invenção também refere-se aos métodos de uso das combinações terapêuticas da presente invenção para tratamento de infecção por HCV ou alívio de um ou mais sintomas da mesma em um paciente. A presente invenção também provê kits compreendendo as combinações da presente invenção.
BRPI0415249-2A 2003-10-11 2004-10-12 terapia de combinação para infecção por hcv BRPI0415249A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51073303P 2003-10-11 2003-10-11
PCT/US2004/033739 WO2005037274A1 (en) 2003-10-11 2004-10-12 Combination therapy for hcv infection

Publications (1)

Publication Number Publication Date
BRPI0415249A true BRPI0415249A (pt) 2006-12-12

Family

ID=34465143

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415249-2A BRPI0415249A (pt) 2003-10-11 2004-10-12 terapia de combinação para infecção por hcv

Country Status (17)

Country Link
US (1) US20050112093A1 (pt)
EP (1) EP1670462A1 (pt)
JP (1) JP2007508326A (pt)
KR (1) KR20060120037A (pt)
CN (1) CN1882335A (pt)
AR (1) AR045870A1 (pt)
AU (1) AU2004281747A1 (pt)
BR (1) BRPI0415249A (pt)
CA (1) CA2541857A1 (pt)
IL (1) IL174864A0 (pt)
MX (1) MXPA06004077A (pt)
NO (1) NO20062104L (pt)
PE (1) PE20050477A1 (pt)
RU (1) RU2006115916A (pt)
TW (1) TW200528104A (pt)
WO (1) WO2005037274A1 (pt)
ZA (1) ZA200602912B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1019A (en) 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
US20120201883A1 (en) * 2004-05-21 2012-08-09 Accu-Break Technologies, Inc Antiviral compositons
TWI437990B (zh) * 2004-10-29 2014-05-21 Vertex Pharma Vx-950之醫藥用途
AU2006275413B2 (en) * 2005-08-02 2012-07-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
WO2007109080A2 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
WO2008106058A2 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
FR2928146B1 (fr) * 2008-02-28 2010-02-19 Saint Gobain Isover Produit a base de fibres minerales et son procede d'obtention.
PE20110343A1 (es) * 2008-09-17 2011-06-25 Boehringer Ingelheim Int Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina
WO2010093843A2 (en) * 2009-02-12 2010-08-19 Vertex Pharmaceuticals Incorporated Hcv combination therapies
EP2450051A4 (en) * 2009-06-30 2012-12-19 Meiji Seika Pharma Co Ltd MEDICAL AGENT AND METHOD FOR THE TREATMENT OF HARD-ANGLE CHRONIC HEPATITIS C
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
WO2017062840A1 (en) * 2015-10-09 2017-04-13 Trek Therapeutics, Pbc Combination therapy for the treatment of hepatitis c virus
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
WO2017223178A1 (en) * 2016-06-21 2017-12-28 Trek Therapeutics, Pbc Treating viral infections with impdh inhibitors
KR101991365B1 (ko) * 2017-03-14 2019-06-21 국립암센터 C형 간염 바이러스 질환 치료를 위한 리고세르팁의 신규 용도
CN109745315B (zh) * 2019-03-08 2021-04-16 中国农业科学院兰州兽医研究所 一种Merimepodib在制备预防口蹄疫病毒感染的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2252465C (en) * 1996-04-23 2007-07-03 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
CA2331823A1 (en) * 1998-05-15 1999-11-25 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection
US6824769B2 (en) * 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
AU2003249659A1 (en) * 2002-05-31 2003-12-19 Schering Corporation Combination therapy for rna virus infections involving ribavirin and impdh inhibitors

Also Published As

Publication number Publication date
IL174864A0 (en) 2008-04-13
ZA200602912B (en) 2007-06-27
AU2004281747A1 (en) 2005-04-28
JP2007508326A (ja) 2007-04-05
AR045870A1 (es) 2005-11-16
CN1882335A (zh) 2006-12-20
MXPA06004077A (es) 2006-06-27
KR20060120037A (ko) 2006-11-24
RU2006115916A (ru) 2007-12-10
WO2005037274A1 (en) 2005-04-28
EP1670462A1 (en) 2006-06-21
NO20062104L (no) 2006-05-10
PE20050477A1 (es) 2005-08-24
CA2541857A1 (en) 2005-04-28
US20050112093A1 (en) 2005-05-26
TW200528104A (en) 2005-09-01

Similar Documents

Publication Publication Date Title
BRPI0415249A (pt) terapia de combinação para infecção por hcv
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
AU4550801A (en) Herbal composition phy906 and its use in chemotheraphy
BRPI0414062A (pt) uso de ciclosporinas midificadas para o tratamento de distúrbios por hcv
BRPI0409125A (pt) terapia de combinação para constipação compreendendo um laxativo e um antagonista de opióide periférico
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
BR0010612A (pt) Vacinas
BRPI0410503B8 (pt) composição tópica e uso da composição
BR0115162A (pt) Tratamentos antitumorais eficazes
NO20072543L (no) Anti-cancer-behandling
BRPI0407234A (pt) Heterociclos substituìdos
BR0215404A (pt) processo e dispositivo para reduzir dosagem terapêutica
BR0316227A (pt) IsÈmeros posicionais de peg ifn alfa 2a
TW200630105A (en) Herbal composition PHY906 and its use in chemotherapy
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
DOP2002000451A (es) Nuevas ciclohexilsulfonas (agentes terapéuticos)
BRPI0406673A (pt) Método para o tratamento ou profilaxia e composição para uso no tratamento ou profilaxia de um ou mais sintomas de uma infecção por herpes viral em um indivìduo, e, uso de uma composição compreendendo um sal citrato e/ou um succinato
WO2000078800A3 (en) Combined decorin binding protein and outer surface protein compositions and methods of use
BRPI0406985A (pt) Terapia de combinação de hcv
BRPI0616535B8 (pt) uso de fator de tecido (tf) lipidado ou um fragmento funcional do mesmo, produto, uso de um produto, complexo (tf::fxa), uso de um complexo, complexo tf::ncis, complexo tf::fxa:ncis, composição farmacêutica e uso de tf não-lipidado ou um fragmento funcional do mesmo
BR9912153A (pt) Piperazinonas substituìdas e uso terapêuticos das mesmas
BRPI0412009A (pt) composições compreendendo balaglitazona e outros compostos antidiabéticos
BR0109155A (pt) Uso de cdp-colina para o tratamento profilático de isquemia cerebral

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]